Parkinson’s Disease: PET scan and evaluation of memantines pharmacological effect.(Parkinsons sygdom bedømt med PET skanning, herunder memantins farmakologiske effekt.) - N/A

Phase 1

• Conditions: Parkinson's Disease

• Registration Number: EUCTR2004-004139-74-DK
• Lead Sponsor: eurologisk afdeling F

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-03-22
• Last Update Posted: 3 October 2016

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Patients:
1) Idiopathic Parkinson's Disease (ICD-10: G20.9)
2) Age 50-70

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Patients:

1) Any current use of tobacco substances containing nicotine.
2) Conditions prohibiting MR scan (implanted pacemaker, protheses etc.)
3) Brain diseases apart from Parkinson's Disease (Aneurisms, AV-malformations, stroke, cranial trauma, dementia etc.)
4) Psychiatric disorders (Schizophrenia, bi-polar mood disorder, depression)
5) Other major diseases (heartfailure, arhytmias, infarcts, kidney failure, liver failure, cirrhosis, active hepatitis, portal hypertension etc.)
6) Current use of drugs with major influence on CNS (eg. amphetamine, metamphetamine, cocaine, opioids, antipsychotics, antiepileptics, NMDA-antagonists)
7) Current use of the anti-parkinsonian drugs Cabergolin and Amantadine.
8) Pregnancy

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified